2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18470%2F21%3A50017522" target="_blank" >RIV/62690094:18470/21:50017522 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216275:25310/21:39917578 RIV/60162694:G44__/21:00556800 RIV/00179906:_____/21:10425526

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0223523420310849?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0223523420310849?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejmech.2020.113112" target="_blank" >10.1016/j.ejmech.2020.113112</a>

Jazyk výsledku

angličtina

Název v původním jazyce

2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease

Popis výsledku v původním jazyce

Alzheimer&apos;s disease is a progressive brain disorder with characteristic symptoms and several pathological hallmarks. The concept of “one drug, one target” has not generated any new drugs since 2004. The new era of drug development in the field of AD builds upon rationally designed multi-target directed ligands that can better address the complexity of AD. Herewith, we designed ten novel derivatives of 2-propargylamino-naphthoquinone. The biological evaluation of these compounds includes inhibition of monoamine oxidase A/B, inhibition of amyloid-beta aggregation, radical-scavenging, and metal-chelating properties. Some of the compounds possess low cytotoxicity profile with an anti-inflammatory ability in the lipopolysaccharide-stimulated cellular model. All these features warrant their further testing in the field of AD. © 2020 Elsevier Masson SAS

Název v anglickém jazyce

2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease

Popis výsledku anglicky

Alzheimer&apos;s disease is a progressive brain disorder with characteristic symptoms and several pathological hallmarks. The concept of “one drug, one target” has not generated any new drugs since 2004. The new era of drug development in the field of AD builds upon rationally designed multi-target directed ligands that can better address the complexity of AD. Herewith, we designed ten novel derivatives of 2-propargylamino-naphthoquinone. The biological evaluation of these compounds includes inhibition of monoamine oxidase A/B, inhibition of amyloid-beta aggregation, radical-scavenging, and metal-chelating properties. Some of the compounds possess low cytotoxicity profile with an anti-inflammatory ability in the lipopolysaccharide-stimulated cellular model. All these features warrant their further testing in the field of AD. © 2020 Elsevier Masson SAS

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30107 - Medicinal chemistry

Projekt

<a href="/cs/project/EF18_069%2F0010054" target="_blank" >EF18_069/0010054: IT4Neuro(degeneration)</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European journal of medicinal chemistry

ISSN

0223-5234

e-ISSN

—

Svazek periodika

211

Číslo periodika v rámci svazku

February

Stát vydavatele periodika

FR - Francouzská republika

Počet stran výsledku

13

Strana od-do

"Article number 113112"

Kód UT WoS článku

000612147700043

EID výsledku v databázi Scopus

2-s2.0-85098158168